Adequate 0 8 0 8 O
baseline 9 17 9 17 O
laboratory 18 28 18 28 O
values 29 35 29 35 O
collected 36 45 36 45 O
no 46 48 46 48 O
more 49 53 49 53 O
than 54 58 54 58 O
7 59 60 59 60 B-lower_bound
days 61 65 61 65 I-lower_bound
before 66 72 66 72 I-lower_bound
starting 73 81 73 81 O
study 82 87 82 87 O
treatment 88 97 88 97 B-treatment

Age 0 3 98 101 B-age
≥ 4 5 102 103 O
80 6 8 104 106 B-lower_bound
years 9 14 107 112 I-lower_bound

Availability 0 12 113 125 O
of 13 15 126 128 O
fresh 16 21 129 134 O
tumor 22 27 135 140 B-cancer
tissue 28 34 141 147 O
and/or 35 41 148 154 O
archival 42 50 155 163 O
tumor 51 56 164 169 O
tissue 57 63 170 176 O
( 64 65 177 178 O
obtained 65 73 178 186 O
within 74 80 187 193 O
5 81 82 194 195 B-upper_bound
years 83 88 196 201 I-upper_bound
of 89 91 202 204 O
the 92 95 205 208 O
consent 96 103 209 216 O
date 104 108 217 221 O
) 108 109 221 222 O
at 110 112 223 225 O
Screening 113 122 226 235 O

Cytomegalovirus 0 15 236 251 B-chronic_disease
( 16 17 252 253 I-chronic_disease
CMV 17 20 253 256 I-chronic_disease
) 20 21 256 257 I-chronic_disease
infection 22 31 258 267 I-chronic_disease
. 31 32 267 268 O
Patients 33 41 269 277 O
who 42 45 278 281 O
are 46 49 282 285 O
CMV 50 53 286 289 O
PCR 54 57 290 293 O
positive 58 66 294 302 O
at 67 69 303 305 O
baseline 70 78 306 314 O
will 79 83 315 319 O
not 84 87 320 323 O
be 88 90 324 326 O
eligible 91 99 327 335 O

Documented 0 10 336 346 O
evidence 11 19 347 355 O
of 20 22 356 358 O
resistance 23 33 359 369 O
to 34 36 370 372 O
prior 37 42 373 378 B-treatment
treatment 43 52 379 388 I-treatment
with 53 57 389 393 I-treatment
idelalisib 58 68 394 404 I-treatment
or 69 71 405 407 I-treatment
other 72 77 408 413 I-treatment
PI3 78 81 414 417 I-treatment
K 81 82 417 418 I-treatment
inhibitors 83 93 419 429 I-treatment

Eastern 0 7 430 437 B-clinical_variable
Cooperative 8 19 438 449 I-clinical_variable
Oncology 20 28 450 458 I-clinical_variable
Group 29 34 459 464 I-clinical_variable
( 35 36 465 466 I-clinical_variable
ECOG 36 40 466 470 I-clinical_variable
) 40 41 470 471 I-clinical_variable
performance 42 53 472 483 I-clinical_variable
status 54 60 484 490 I-clinical_variable
≤ 61 62 491 492 O
2 63 64 493 494 B-upper_bound

Follicular 0 10 495 505 B-cancer
lymphoma(FL 11 22 506 517 I-cancer
) 22 23 517 518 I-cancer
grade1 24 30 519 525 B-lower_bound
- 30 31 525 526 O
2 31 32 526 527 O
- 32 33 527 528 O
3a 33 35 528 530 B-upper_bound

Hepatitis 0 9 531 540 B-chronic_disease
B 10 11 541 542 I-chronic_disease
( 12 13 543 544 I-chronic_disease
HBV 13 16 544 547 I-chronic_disease
) 16 17 547 548 I-chronic_disease
or 18 20 549 551 O
hepatitis 21 30 552 561 B-chronic_disease
C 31 32 562 563 I-chronic_disease
( 33 34 564 565 I-chronic_disease
HCV 34 37 565 568 I-chronic_disease
) 37 38 568 569 I-chronic_disease
. 38 39 569 570 O
Patients 40 48 571 579 O
positive 49 57 580 588 O
for 58 61 589 592 O
HBsAg 62 67 593 598 O
or 68 70 599 601 O
HBcAb 71 76 602 607 O
will 77 81 608 612 O
be 82 84 613 615 O
eligible 85 93 616 624 O
if 94 96 625 627 O
they 97 101 628 632 O
are 102 105 633 636 O
negative 106 114 637 645 O
for 115 118 646 649 O
HBV 119 122 650 653 O
- 122 123 653 654 O
DNA 123 126 654 657 O
, 126 127 657 658 O
these 128 133 659 664 O
patients 134 142 665 673 O
should 143 149 674 680 O
receive 150 157 681 688 O
prophylactic 158 170 689 701 B-treatment
antiviral 171 180 702 711 I-treatment
therapy 181 188 712 719 I-treatment
. 188 189 719 720 O
Patients 190 198 721 729 O
positive 199 207 730 738 O
for 208 211 739 742 O
anti- 212 217 743 748 O
HCV 218 221 749 752 O
antibody 222 230 753 761 O
will 231 235 762 766 O
be 236 238 767 769 O
eligible 239 247 770 778 O
if 248 250 779 781 O
they 251 255 782 786 O
are 256 259 787 790 O
negative 260 268 791 799 O
for 269 272 800 803 O
HCV 273 276 804 807 O
- 276 277 807 808 O
RNA 277 280 808 811 O

Histologically 0 14 812 826 O
confirmed 15 24 827 836 O
diagnosis 25 34 837 846 O
of 35 37 847 849 O
Indolent 38 46 850 858 B-cancer
non 47 50 859 862 I-cancer
- 50 51 862 863 I-cancer
Hodgkin 51 58 863 870 I-cancer
's 58 60 870 872 I-cancer
lymphoma 61 69 873 881 I-cancer
( 70 71 882 883 I-cancer
iNHL 71 75 883 887 I-cancer
) 75 76 887 888 I-cancer
in 77 79 889 891 O
CD20 80 84 892 896 B-cancer
positive 85 93 897 905 O
patients 94 102 906 914 O
, 102 103 914 915 O
with 104 108 916 920 O
histological 109 121 921 933 O
subtype 122 129 934 941 O
limited 130 137 942 949 O
to 138 140 950 952 O

Histologically 0 14 953 967 O
confirmed 15 24 968 977 O
diagnosis 25 34 978 987 O
of 35 37 988 990 O
follicular 38 48 991 1001 B-cancer
lymphoma 49 57 1002 1010 I-cancer
grade 58 63 1011 1016 I-cancer
3b 64 66 1017 1019 I-cancer
or 67 69 1020 1022 O
transformed 70 81 1023 1034 O
disease 82 89 1035 1042 O
, 89 90 1042 1043 O
or 91 93 1044 1046 O
chronic 94 101 1047 1054 B-cancer
lymphocytic 102 113 1055 1066 I-cancer
leukemia 114 122 1067 1075 I-cancer

History 0 7 1076 1083 O
or 8 10 1084 1086 O
concurrent 11 21 1087 1097 O
condition 22 31 1098 1107 O
of 32 34 1108 1110 O
interstitial 35 47 1111 1123 B-chronic_disease
lung 48 52 1124 1128 I-chronic_disease
disease 53 60 1129 1136 I-chronic_disease
of 61 63 1137 1139 O
any 64 67 1140 1143 O
severity 68 76 1144 1152 O
and/or 77 83 1153 1159 O
severely 84 92 1160 1168 O
impaired 93 101 1169 1177 B-chronic_disease
lung 102 106 1178 1182 I-chronic_disease
function 107 115 1183 1191 I-chronic_disease

Known 0 5 1192 1197 O
history 6 13 1198 1205 O
of 14 16 1206 1208 O
human 17 22 1209 1214 B-chronic_disease
immunodeficiency 23 39 1215 1231 I-chronic_disease
virus 40 45 1232 1237 I-chronic_disease
( 46 47 1238 1239 I-chronic_disease
HIV 47 50 1239 1242 I-chronic_disease
) 50 51 1242 1243 I-chronic_disease
infection 52 61 1244 1253 I-chronic_disease

Known 0 5 1254 1259 O
lymphomatous 6 18 1260 1272 B-cancer
involvement 19 30 1273 1284 O
of 31 33 1285 1287 O
the 34 37 1288 1291 O
central 38 45 1292 1299 O
nervous 46 53 1300 1307 O
system 54 60 1308 1314 O

Left 0 4 1315 1319 B-clinical_variable
ventricular 5 16 1320 1331 I-clinical_variable
ejection 17 25 1332 1340 I-clinical_variable
fraction 26 34 1341 1349 I-clinical_variable
≥ 35 36 1350 1351 O
45 37 39 1352 1354 B-lower_bound
% 39 40 1354 1355 I-lower_bound

Life 0 4 1356 1360 B-clinical_variable
expectancy 5 15 1361 1371 I-clinical_variable
of 16 18 1372 1374 O
at 19 21 1375 1377 O
least 22 27 1378 1383 O
3 28 29 1384 1385 B-lower_bound
months 30 36 1386 1392 I-lower_bound

Lymphoplasmacytoid 0 18 1393 1411 B-cancer
lymphoma 19 27 1412 1420 I-cancer
/ 27 28 1420 1421 O
Waldenström 28 39 1421 1432 B-cancer
macroglobulinemia 40 57 1433 1450 I-cancer
( 58 59 1451 1452 O
LPL 59 62 1452 1455 B-cancer
/ 62 63 1455 1456 O
WM 63 65 1456 1458 B-cancer
) 65 66 1458 1459 O

Male 0 4 1460 1464 B-gender

Marginal 0 8 1465 1473 B-chronic_disease
zone 9 13 1474 1478 I-chronic_disease
lymphoma 14 22 1479 1487 I-chronic_disease
( 23 24 1488 1489 I-chronic_disease
MZL 24 27 1489 1492 I-chronic_disease
) 27 28 1492 1493 I-chronic_disease
( 29 30 1494 1495 O
splenic 30 37 1495 1502 O
, 37 38 1502 1503 O
nodal 39 44 1504 1509 O
, 44 45 1509 1510 O
or 46 48 1511 1513 O
extra 49 54 1514 1519 O
- 54 55 1519 1520 O
nodal 55 60 1520 1525 O
) 60 61 1525 1526 O

Non 0 3 1527 1530 O
- 3 4 1530 1531 O
WM 4 6 1531 1533 O
must 7 11 1534 1538 O
have 12 16 1539 1543 O
at 17 19 1544 1546 O
least 20 25 1547 1552 O
one 26 29 1553 1556 B-lower_bound
bi 30 32 1557 1559 O
- 32 33 1559 1560 O
dimensionally 33 46 1560 1573 O
measurable 47 57 1574 1584 O
lesion 58 64 1585 1591 O
( 65 66 1592 1593 O
which 66 71 1593 1598 O
has 72 75 1599 1602 O
not 76 79 1603 1606 O
been 80 84 1607 1611 O
previously 85 95 1612 1622 O
irradiated 96 106 1623 1633 O
) 106 107 1633 1634 O
according 108 117 1635 1644 O
to 118 120 1645 1647 O
the 121 124 1648 1651 O
Lugano 125 131 1652 1658 O
Classification 132 146 1659 1673 O
. 146 147 1673 1674 O
For 148 151 1675 1678 O
patients 152 160 1679 1687 O
with 161 165 1688 1692 O
splenic 166 173 1693 1700 O
MZL 174 177 1701 1704 O
( 178 179 1705 1706 O
Marginal 179 187 1706 1714 O
- 187 188 1714 1715 O
zone 188 192 1715 1719 O
lymphoma 193 201 1720 1728 O
) 201 202 1728 1729 O
this 203 207 1730 1734 O
requirement 208 219 1735 1746 O
may 220 223 1747 1750 O
be 224 226 1751 1753 O
restricted 227 237 1754 1764 O
to 238 240 1765 1767 O
splenomegaly 241 253 1768 1780 O
alone 254 259 1781 1786 O
since 260 265 1787 1792 O
that 266 270 1793 1797 O
is 271 273 1798 1800 O
usually 274 281 1801 1808 O
the 282 285 1809 1812 O
only 286 290 1813 1817 O
manifestation 291 304 1818 1831 O
of 305 307 1832 1834 O
measurable 308 318 1835 1845 O
disease 319 326 1846 1853 O

Patients 0 8 1854 1862 O
affected 9 17 1863 1871 O
by 18 20 1872 1874 O
WM 21 23 1875 1877 B-cancer
who 24 27 1878 1881 O
do 28 30 1882 1884 O
not 31 34 1885 1888 O
have 35 39 1889 1893 O
at 40 42 1894 1896 O
least 43 48 1897 1902 O
one 49 52 1903 1906 B-lower_bound
bi 53 55 1907 1909 O
- 55 56 1909 1910 O
dimensionally 56 69 1910 1923 O
measurable 70 80 1924 1934 O
lesion 81 87 1935 1941 O
in 88 90 1942 1944 O
the 91 94 1945 1948 O
baseline 95 103 1949 1957 O
radiologic 104 114 1958 1968 O
assessment 115 125 1969 1979 O
must 126 130 1980 1984 O
have 131 135 1985 1989 O
measurable 136 146 1990 2000 O
disease 147 154 2001 2008 O
, 154 155 2008 2009 O
defined 156 163 2010 2017 O
as 164 166 2018 2020 O
presence 167 175 2021 2029 O
of 176 178 2030 2032 O
immunoglobulin 179 193 2033 2047 O
M 194 195 2048 2049 O
( 196 197 2050 2051 O
IgM 197 200 2051 2054 O
) 200 201 2054 2055 O
paraprotein 202 213 2056 2067 O
with 214 218 2068 2072 O
a 219 220 2073 2074 O
minimum 221 228 2075 2082 O
IgM 229 232 2083 2086 B-clinical_variable
level 233 238 2087 2092 I-clinical_variable
≥ 239 240 2093 2094 O
2 241 242 2095 2096 B-lower_bound
x 243 244 2097 2098 I-lower_bound
upper 245 250 2099 2104 I-lower_bound
limit 251 256 2105 2110 I-lower_bound
of 257 259 2111 2113 I-lower_bound
normal 260 266 2114 2120 I-lower_bound
( 267 268 2121 2122 I-lower_bound
ULN 268 271 2122 2125 I-lower_bound
) 271 272 2125 2126 I-lower_bound
and 273 276 2127 2130 O
positive 277 285 2131 2139 O
immunofixation 286 300 2140 2154 B-treatment
test 301 305 2155 2159 O

Patients 0 8 2160 2168 O
must 9 13 2169 2173 O
have 14 18 2174 2178 O
relapsed 19 27 2179 2187 O
( 28 29 2188 2189 O
recurrence 29 39 2189 2199 O
after 40 45 2200 2205 O
complete 46 54 2206 2214 O
response 55 63 2215 2223 O
or 64 66 2224 2226 O
presented 67 76 2227 2236 O
progression 77 88 2237 2248 O
after 89 94 2249 2254 O
partial 95 102 2255 2262 O
response 103 111 2263 2271 O
) 111 112 2271 2272 O
after 113 118 2273 2278 O
last 119 123 2279 2283 O
rituximab 124 133 2284 2293 B-treatment
- 133 134 2293 2294 I-treatment
containing 134 144 2294 2304 I-treatment
therapy 145 152 2305 2312 I-treatment
( 153 154 2313 2314 O
other 154 159 2314 2319 B-treatment
previous 160 168 2320 2328 I-treatment
treatment 169 178 2329 2338 I-treatment
lines 179 184 2339 2344 I-treatment
after 185 190 2345 2350 O
rituximab 191 200 2351 2360 O
are 201 204 2361 2364 O
allowed 205 212 2365 2372 O
) 212 213 2372 2373 O
. 213 214 2373 2374 O
A 215 216 2375 2376 O
previous 217 225 2377 2385 B-treatment
regimen 226 233 2386 2393 I-treatment
is 234 236 2394 2396 O
defined 237 244 2397 2404 O
as 245 247 2405 2407 O
one 248 251 2408 2411 O
of 252 254 2412 2414 O
the 255 258 2415 2418 O
following 259 268 2419 2428 O
: 268 269 2428 2429 O
at 270 272 2430 2432 O
least 273 278 2433 2438 O
2 279 280 2439 2440 O
months 281 287 2441 2447 O
of 288 290 2448 2450 O
single 291 297 2451 2457 B-treatment
- 297 298 2457 2458 I-treatment
agent 298 303 2458 2463 I-treatment
therapy 304 311 2464 2471 I-treatment
( 312 313 2472 2473 O
less 313 317 2473 2477 O
than 318 322 2478 2482 O
2 323 324 2483 2484 O
months 325 331 2485 2491 O
of 332 334 2492 2494 O
therapy 335 342 2495 2502 O
is 343 345 2503 2505 O
allowed 346 353 2506 2513 O
for 354 357 2514 2517 O
patients 358 366 2518 2526 O
who 367 370 2527 2530 O
responded 371 380 2531 2540 O
to 381 383 2541 2543 O
single 384 390 2544 2550 B-treatment
- 390 391 2550 2551 I-treatment
agent 391 396 2551 2556 I-treatment
rituximab 397 406 2557 2566 I-treatment
) 406 407 2566 2567 O
; 407 408 2567 2568 O
at 409 411 2569 2571 O
least 412 417 2572 2577 O
2 418 419 2578 2579 O
consecutive 420 431 2580 2591 O
cycles 432 438 2592 2598 O
of 439 441 2599 2601 O
polychemotherapy 442 458 2602 2618 B-treatment
; 458 459 2618 2619 O
autologous 460 470 2620 2630 B-treatment
transplant 471 481 2631 2641 I-treatment
; 481 482 2641 2642 O
radioimmunotherapy 483 501 2643 2661 B-treatment
. 501 502 2661 2662 O
Previous 503 511 2663 2671 O
exposure 512 520 2672 2680 O
to 521 523 2681 2683 O
PI3 524 527 2684 2687 B-treatment
K 527 528 2687 2688 I-treatment
is 529 531 2689 2691 O
acceptable 532 542 2692 2702 O
( 543 544 2703 2704 O
except 544 550 2704 2710 O
to 551 553 2711 2713 O
copanlisib 554 564 2714 2724 B-treatment
) 564 565 2724 2725 O
provided 566 574 2726 2734 O
there 575 580 2735 2740 O
is 581 583 2741 2743 O
no 584 586 2744 2746 O
resistance 587 597 2747 2757 O
. 597 598 2757 2758 O
Patients 599 607 2759 2767 O
with 608 612 2768 2772 O
prior 613 618 2773 2778 O
intolerance 619 630 2779 2790 O
to 631 633 2791 2793 O
PI3 634 637 2794 2797 B-treatment
K 637 638 2797 2798 I-treatment
inhibitors 639 649 2799 2809 I-treatment
other 650 655 2810 2815 O
than 656 660 2816 2820 O
copanlisib 661 671 2821 2831 O
are 672 675 2832 2835 O
eligible 676 684 2836 2844 O

Patients 0 8 2845 2853 O
with 9 13 2854 2858 O
HbA1c 14 19 2859 2864 B-clinical_variable
> 20 21 2865 2866 O
8.5 22 25 2867 2870 B-lower_bound
% 25 26 2870 2871 I-lower_bound
at 27 29 2872 2874 O
Screening 30 39 2875 2884 O

Prior 0 5 2885 2890 B-treatment
treatment 6 15 2891 2900 I-treatment
with 16 20 2901 2905 O
copanlisib 21 31 2906 2916 B-treatment

Progression 0 11 2917 2928 O
free 12 16 2929 2933 O
interval 17 25 2934 2942 O
or 26 28 2943 2945 O
treatment 29 38 2946 2955 B-treatment
free 39 43 2956 2960 O
interval 44 52 2961 2969 O
of 53 55 2970 2972 O
less 56 60 2973 2977 O
than 61 65 2978 2982 O
12 66 68 2983 2985 B-upper_bound
months 69 75 2986 2992 I-upper_bound
since 76 81 2993 2998 O
the 82 85 2999 3002 O
last 86 90 3003 3007 O
rituximab 91 100 3008 3017 B-treatment
containing 101 111 3018 3028 O
treatment 112 121 3029 3038 O
( 122 123 3039 3040 O
including 123 132 3040 3049 O
rituximab 133 142 3050 3059 O
maintenance 143 154 3060 3071 O
) 154 155 3071 3072 O
. 155 156 3072 3073 O
For 157 160 3074 3077 O
patients 161 169 3078 3086 O
considered 170 180 3087 3097 O
unwilling 181 190 3098 3107 O
/ 190 191 3107 3108 O
unfit 191 196 3108 3113 O
to 197 199 3114 3116 O
receive 200 207 3117 3124 O
chemotherapy 208 220 3125 3137 B-treatment
: 221 222 3138 3139 O
progression 223 234 3140 3151 O
free 235 239 3152 3156 O
interval 240 248 3157 3165 O
or 249 251 3166 3168 O
treatment 252 261 3169 3178 O
free 262 266 3179 3183 O
interval 267 275 3184 3192 O
of 276 278 3193 3195 O
less 279 283 3196 3200 O
than 284 288 3201 3205 O
6 289 290 3206 3207 B-upper_bound
months 291 297 3208 3214 I-upper_bound
since 298 303 3215 3220 O
the 304 307 3221 3224 O
last 308 312 3225 3229 O
rituximab 313 322 3230 3239 O
containing 323 333 3240 3250 O
treatment 334 343 3251 3260 O
( 344 345 3261 3262 O
including 345 354 3262 3271 O
rituximab 355 364 3272 3281 O
maintenance 365 376 3282 3293 O
) 376 377 3293 3294 O
, 377 378 3294 3295 O
as 379 381 3296 3298 O
assessed 382 390 3299 3307 O
by 391 393 3308 3310 O
the 394 397 3311 3314 O
investigator 398 410 3315 3327 O

Small 0 5 3328 3333 B-cancer
lymphocytic 6 17 3334 3345 I-cancer
lymphoma(SLL 18 30 3346 3358 I-cancer
) 30 31 3358 3359 I-cancer
with 32 36 3360 3364 O
absolute 37 45 3365 3373 B-clinical_variable
lymphocyte 46 56 3374 3384 I-clinical_variable
count 57 62 3385 3390 I-clinical_variable
< 63 64 3391 3392 O
5x10 64 68 3392 3396 B-upper_bound
* 68 69 3396 3397 I-upper_bound
9 69 70 3397 3398 I-upper_bound
/ 70 71 3398 3399 I-upper_bound
L 71 72 3399 3400 I-upper_bound
at 73 75 3401 3403 O
study 76 81 3404 3409 O
entry 82 87 3410 3415 O

at 0 2 3416 3418 O
least 3 8 3419 3424 O
1 9 10 3425 3426 B-lower_bound
grade 11 16 3427 3432 O
4 17 18 3433 3434 O
CIRS 19 23 3435 3439 O
- 23 24 3439 3440 O
G 24 25 3440 3441 O
comorbidity 26 37 3442 3453 O
( 38 39 3454 3455 O
if 39 41 3455 3457 O
compatible 42 52 3458 3468 O
to 53 55 3469 3471 O
participation 56 69 3472 3485 O
in 70 72 3486 3488 O
the 73 76 3489 3492 O
study 77 82 3493 3498 O
) 82 83 3498 3499 O

at 0 2 3500 3502 O
least 3 8 3503 3508 O
3 9 10 3509 3510 B-lower_bound
grade 11 16 3511 3516 B-clinical_variable
3 17 18 3517 3518 I-clinical_variable
CIRS 19 23 3519 3523 I-clinical_variable
- 23 24 3523 3524 I-clinical_variable
G 24 25 3524 3525 I-clinical_variable
comorbidities 26 39 3526 3539 I-clinical_variable

be 0 2 3540 3542 O
considered 3 13 3543 3553 O
unfit 14 19 3554 3559 O
to 20 22 3560 3562 O
receive 23 30 3563 3570 O
chemotherapy 31 43 3571 3583 B-treatment
on 44 46 3584 3586 O
reason 47 53 3587 3593 O
of 54 56 3594 3596 O
age 57 60 3597 3600 B-age
, 60 61 3600 3601 O
concomitant 62 73 3602 3613 O
morbidities 74 85 3614 3625 O
, 85 86 3625 3626 O
and/or 87 93 3627 3633 O
residual 94 102 3634 3642 O
toxicity 103 111 3643 3651 O
from 112 116 3652 3656 O
previous 117 125 3657 3665 B-treatment
treatments 126 136 3666 3676 I-treatment
, 136 137 3676 3677 O
or 138 140 3678 3680 O
unwillingness 141 154 3681 3694 O
to 155 157 3695 3697 O
receive 158 165 3698 3705 O
chemotherapy 166 178 3706 3718 O
. 178 179 3718 3719 O
These 180 185 3720 3725 O
patients 186 194 3726 3734 O
must 195 199 3735 3739 O
also 200 204 3740 3744 O
have 205 209 3745 3749 O
had 210 213 3750 3753 O
a 214 215 3754 3755 O
progression 216 227 3756 3767 O
- 227 228 3767 3768 O
free 228 232 3768 3772 O
and 233 236 3773 3776 O
treatment 237 246 3777 3786 O
- 246 247 3786 3787 O
free 247 251 3787 3791 O
interval 252 260 3792 3800 O
of 261 263 3801 3803 O
at 264 266 3804 3806 O
least 267 272 3807 3812 O
6 273 274 3813 3814 B-upper_bound
months 275 281 3815 3821 I-upper_bound
after 282 287 3822 3827 I-upper_bound
completion 288 298 3828 3838 O
of 299 301 3839 3841 O
the 302 305 3842 3845 O
last 306 310 3846 3850 O
rituximab 311 320 3851 3860 B-treatment
- 320 321 3860 3861 I-treatment
containing 321 331 3861 3871 I-treatment
treatment 332 341 3872 3881 I-treatment
. 341 342 3881 3882 O
Patients 343 351 3883 3891 O
in 352 354 3892 3894 O
whom 355 359 3895 3899 O
chemotherapy 360 372 3900 3912 O
is 373 375 3913 3915 O
contraindicated 376 391 3916 3931 O
are 392 395 3932 3935 O
defined 396 403 3936 3943 O
by 404 406 3944 3946 O
one 407 410 3947 3950 O
of 411 413 3951 3953 O
the 414 417 3954 3957 O
following 418 427 3958 3967 O
features 428 436 3968 3976 O

female 0 6 3977 3983 B-gender

have 0 4 3984 3988 O
had 5 8 3989 3992 O
a 9 10 3993 3994 O
progression 11 22 3995 4006 O
- 22 23 4006 4007 O
free 23 27 4007 4011 O
and 28 31 4012 4015 O
treatment 32 41 4016 4025 B-treatment
- 41 42 4025 4026 O
free 42 46 4026 4030 O
interval 47 55 4031 4039 O
of 56 58 4040 4042 O
at 59 61 4043 4045 O
least 62 67 4046 4051 O
12 68 70 4052 4054 B-lower_bound
months 71 77 4055 4061 I-lower_bound
after 78 83 4062 4067 I-lower_bound
completion 84 94 4068 4078 O
of 95 97 4079 4081 O
the 98 101 4082 4085 O
last 102 106 4086 4090 O
rituximab 107 116 4091 4100 B-treatment
- 116 117 4100 4101 O
containing 117 127 4101 4111 O
treatment 128 137 4112 4121 O

≥ 0 1 4122 4123 O
18 2 4 4124 4126 B-lower_bound
years 5 10 4127 4132 I-lower_bound
of 11 13 4133 4135 O
age 14 17 4136 4139 B-age

